Galapagos completes recruitment of NOVESA trial in systemic sclerosis
(WorldNews Belgium)

Galapagos completes recruitment of NOVESA trial in systemic sclerosis 05 Dec 2019 22:01 CET Company Name GALAPAGOS ISN BE0003818359 Market Euronext Symbol GLPG Galapagos completes recruitment of NOVESA trial in systemic sclerosis Mechelen, Belgium; 5 December 2019, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) has completed recruitment for the NOVESA Phase 2 clinical trial with GLPG1690. NOVESA is a double-blind, placebo-controlled Phase 2a trial evaluating the efficacy, safety and PK/PD of GLPG1690 in patients with systemic sclerosis (SSc), an autoimmune disease involving multiorgan fibrosis which has one of the highest mortality rates among rheumatic diseases1. NOVESA recruited 33...